肾宁合剂治疗IgA肾病的临床研究
[Clinical study on Shenning Mixture in treating IgA nephropathy].
作者信息
Bo S, Ju J, Chu D
机构信息
Yuhuangding Hospital, Yantai City, Shandong 264000.
出版信息
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Oct;20(10):729-30.
OBJECTIVE
To study the clinical therapeutic effect of Shenning Mixture (SNM) in treating IgA nephropathy.
METHODS
Patients were treated separately with SNM or prednisone by randomized grouping. The criteria, including clinical symptoms, signs, hematuria, albuminuria and immune globulin were observed.
RESULTS
The total effective rate and the complete remission rate in the SNM group were 97.1% and 45.7% respectively, while in the control group, they were 37.1% and 8.6% respectively. Comparison of the two groups showed that the therapeutic effect in the former was better than that in the latter significantly, P < 0.01. The hematuria and albuminuria extenuated and serum IgA lowered more significantly in the SNM group than those in the control group (P < 0.05, P < 0.01).
CONCLUSION
SNM has obvious therapeutic effect on the hematuria and albuminuria in treating IgA nephropathy.
目的
研究肾宁合剂治疗IgA肾病的临床疗效。
方法
将患者随机分组，分别用肾宁合剂或泼尼松进行治疗。观察包括临床症状、体征、血尿、蛋白尿及免疫球蛋白等指标。
结果
肾宁合剂组总有效率和完全缓解率分别为97.1%和45.7%，而对照组分别为37.1%和8.6%。两组比较显示，前者治疗效果明显优于后者，P<0.01。肾宁合剂组血尿、蛋白尿减轻及血清IgA降低程度均明显大于对照组（P<0.05，P<0.01）。
结论
肾宁合剂治疗IgA肾病的血尿和蛋白尿疗效显著。
Zotero 插件